A Phase 3 interventional study of Comparator: etoricoxib and Comparator: ibuprofen in Postoperative Dental Pain, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing etoricoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Etoricoxib · Pain.
Among the 14 studies testing etoricoxib in Pain, this one has the largest enrollment, is one of 2 that started in 2008, is the only one in phase 3, and was the 2nd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 14 studies testing etoricoxib in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 9
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 588 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 75 across the 14 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 6 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing etoricoxib in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the pain relieving effect of different doses of MK0663 with placebo and other pain relievers/analgesics in patients with postoperative dental pain. Pain intensity and relief will be measured by the total pain relief score (TOPAR) and patient evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
etoricoxib 90 mg
Drug: Comparator: etoricoxib
etoricoxib 120 mg
Drug: Comparator: etoricoxib
ibuprofen 2400 mg
Drug: Comparator: ibuprofen
acetaminophen 2400 mg/codeine 240 mg
Drug: Comparator: acetaminophen + codeine
Matching Placebo
Drug: Comparator: placebo
etoricoxib 90 mg; 120 mg (once daily) over three days.
ibuprofen 2400 mg (600 mg Q6h) over three Days
Drug pages: Acetaminophen · Codeine
acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
matching placebo over three Days
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)
TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point Likert scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24.
Time frame: Over the first 6 hours post the initial Day 1 dose of the study medication
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication
Patient's Global Assessment of Study Medication was on 0- to 4- point scale, with 0=Poor, and 4=Excellent for patient's rating of the study medication for pain.
Time frame: At 24 hours post the initial Day 1 dose of the study medication
Study Conducted at 3 investigational sites in the US. Patients were recruited from the sites patient pool and through advertising. A total of 588 patients were randomized. First Patient Entered 27-June-2008; First Patient In (randomized) on 03-July- 2008; Last Patient Last Visit 08-Jan-09
| Milestone | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg |
|---|---|---|---|---|---|
| Started | 46 | 191 | 97 | 192 | 62 |
| Completed | 45 | 188 | 95 | 189 | 56 |
| Not completed | 1 | 3 | 2 | 3 | 6 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 1 | 2 |
TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point Likert scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24.
| Units on a Scale | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg |
|---|---|---|---|---|---|
| Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6) | 5.08 ± 0.86 | 16.10 ± 0.42 | 15.73 ± 0.59 | 15.67 ± 0.42 | 11.83 ± 0.74 |
Patient's Global Assessment of Study Medication was on 0- to 4- point scale, with 0=Poor, and 4=Excellent for patient's rating of the study medication for pain.
| Participants | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg |
|---|---|---|---|---|---|
| Poor | 19 | 12 | 7 | 6 | 1 |
| Fair | 12 | 12 | 5 | 24 | 13 |
| Good | 5 | 43 | 20 | 42 | 15 |
| Very Good | 5 | 66 | 26 | 73 | 18 |
| Excellent | 3 | 51 | 28 | 35 | 7 |
Collected over Adverse experiences were collected from the Pre-surgery/Pre-treatment period through the 14 day safety follow-up period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/46 (0%) | 12/46 (26.1%) |
| Etoricoxib 90 mg | — | 0/191 (0%) | 54/191 (28.3%) |
| Etoricoxib 120 mg | — | 0/97 (0%) | 28/97 (28.9%) |
| Ibuprofen 2400 mg | — | 0/192 (0%) | 57/192 (29.7%) |
| Acetaminophen 2400 mg/Codeine 240 mg | — | 0/62 (0%) | 35/62 (56.5%) |
| Event | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/46 | 6/191 | 4/97 | 10/192 | 23/62 |
| VomitingGastrointestinal disorders | 1/46 | 2/191 | 1/97 | 2/192 | 15/62 |
| DizzinessNervous system disorders | 2/46 | 4/191 | 0/97 | 3/192 | 10/62 |
| HeadacheNervous system disorders | 6/46 | 11/191 | 5/97 | 8/192 | 9/62 |
| SomnolenceNervous system disorders | 0/46 | 4/191 | 2/97 | 6/192 | 5/62 |
| FlushingVascular disorders | 2/46 | 0/191 | 1/97 | 1/192 | 0/62 |
| Alveolar osteitisInfections and infestations | 0/46 | 8/191 | 3/97 | 8/192 | 1/62 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/46 | 1/191 | 1/97 | 1/192 | 2/62 |
| DysgeusiaNervous system disorders | 0/46 | 2/191 | 3/97 | 0/192 | 0/62 |
| BlepharospasmEye disorders | 1/46 | 0/191 | 0/97 | 0/192 | 0/62 |
| Age, Continuous(years) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 21.0 ± 3.0 | 21.8 ± 3.6 | 21.8 ± 3.5 | 21.6 ± 3.8 | 20.5 ± 2.8 | 21.5 ± 3.5 |
| Sex: Female, Male(Participants) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Female | 25 | 113 | 50 | 115 | 37 | 340 |
| Male | 21 | 78 | 47 | 77 | 25 | 248 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 52 | 25 | 50 | 17 | 155 |
| Not Hispanic or Latino | 35 | 139 | 72 | 142 | 44 | 432 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 2 | 1 | 1 | 5 |
| Asian | 0 | 6 | 4 | 9 | 0 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 1 | 1 | 4 |
| Black or African American | 2 | 4 | 1 | 7 | 3 | 17 |
| White | 43 | 174 | 86 | 173 | 56 | 532 |
| More than one race | 1 | 5 | 3 | 1 | 1 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Pain Intensity(Participants) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Moderate | 21 | 98 | 49 | 106 | 30 | 304 |
| Severe | 25 | 93 | 48 | 86 | 32 | 284 |
| Body Weight(Kilograms) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 71.21 ± 16.33 | 72.53 ± 16.68 | 71.02 ± 15.96 | 72.24 ± 16.81 | 69.43 ± 13.99 | 71.76 ± 16.29 |
| Duration of Surgery(Hours) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 0.14 ± 0.06 | 0.13 ± 0.06 | 0.15 ± 0.08 | 0.14 ± 0.06 | 0.13 ± 0.06 | 0.14 ± 0.06 |
| Height(Centimeters) | Placebo | Etoricoxib 90 mg | Etoricoxib 120 mg | Ibuprofen 2400 mg | Acetaminophen 2400 mg/Codeine 240 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 171.03 ± 8.91 | 168.39 ± 9.95 | 167.92 ± 10.07 | 168.50 ± 9.05 | 168.38 ± 9.86 | 168.56 ± 9.59 |
3 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Jun 2008, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib